Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
复制标题
DOI：
10.4269/ajtmh.1999.60.936
复制
发表时间：
1999-06-01
影响因子：
3.3
通讯作者：
Looareesuwan, S
中科院分区：
文献类型：
--
作者：
van Vugt, M;Wilairatana, P;Looareesuwan, S
新的口服固定复方蒿甲醚-甲氟曲明（CGP 56697）已被证明是治疗多重耐药恶性疟原虫疟疾的一种有效且耐受性良好的方法，尽管使用四剂量方案的治愈率低于目前推荐的替代方案青蒿琥酯-甲氟喹。因此，在一项涉及359例无并发症多药耐药恶性疟疾患者的双盲试验中，将两种六剂量方案（成人总剂量= 480毫克蒿甲醚和2880毫克氨苯曲明）与以前使用的四剂量方案（320毫克蒿甲醚和1,920毫克氨苯曲明）进行了比较。三个治疗组在寄生虫和发热清除时间以及报告的不良反应方面没有差异。两种六剂量方案的调整28天治愈率分别为96.9%和99.12%，而四剂量方案的调整28天治愈率为83.3% （P < 0.001）。这些六剂量的蒿甲醚-氨苯曲明方案为耐多药恶性疟疾提供了一种非常有效且耐受性良好的治疗方法。
The new oral fixed combination artemether-lumefantrine (CGP 56697) has proved to be an effective and well-tolerated treatment of multi-drug resistant Plasmodium falciparum malaria, although cure rates using the four-dose regimen have been lower than with the currently recommended alternative of artesunate-mefloquine. Two six-dose schedules (total adult dose = 480 mg of artemether and 2,880 mg of lumefantrine) were therefore compared with the previously used four-dose regimen (320 mg of artemether and 1,920 mg of lumefantrine) in a double-blind trial involving 359 patients with uncomplicated multidrug-resistant falciparum malaria. There were no differences between the three treatment groups in parasite and fever clearance times, and reported adverse effects. The two six-dose regimens gave adjusted 28-day cure rates of 96.9% and 99.12%, respectively, compared with 83.3% for the four-dose regimen (P < 0.001). These six-dose regimens of artemether-lumefantrine provide a highly effective and very well-tolerated treatment for multidrug-resistant falciparum malaria.